 - Takeda concludes $13 billion acquisition of Nycomed
Takeda Pharmaceutical finalized its purchase of Nycomed for $13 billion. Frank Morich was named Nycomed's CEO while retaining his post as executive vice president of global operations for America and Europe at a Takeda America Holdings unit. The merger "significantly broadens our coverage of the global pharmaceutical market to more than 70 countries, increasing our global [prescription] sales ranking to 12th and further strengthening our position in the industry," Morich said. Drug Store News (9/30)        - Study: Molecule stops chronic lymphocytic leukemia in blood samples
A molecule called PHA-767491 eliminates chronic lymphocytic leukemia cells in blood samples and could target dividing leukemia cells in lymph nodes, according to an Irish study published in Molecular Cancer Therapeutics. Results of the preclinical study gives "some hope for the future, especially as related trials with patients are already under way," said Corrado Santocanale of the National University of Ireland, Galway. Galway Advertiser (Ireland) (9/29) - Experimental drug shows promise for mixed-lineage leukemia
 A drug candidate called I-BET151 functions like a chemical tag that plays a role in blocking the activation of genes linked to mixed-lineage leukemia, the most common form of leukemia in infants, according to a British study published in the journal Nature. Findings showed that the drug can halt the progression of the disease in mice and human cancer cells. The results could pave the way for the start of Phase I human trials. Reuters (10/2)  |  |  | | FREE TRIAL – Thomson Reuters Cortellis™ Pipeline Intelligence
Discover new opportunities in drug development and licensing faster. Cortellis gives you an innovative way of finding and acting on drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, intuitively presented.
Click here to see if you qualify for a free trial! | |  |  |  |
 - Report: Massachusetts' $1B life sciences program sees ROI
The $217 million in funding appropriated for the Massachusetts biotech sector as part of Gov. Deval Patrick's $1 billion life sciences program over 10 years has resulted in $754 million in outside investments, generated 1,965 jobs and is expected to create 5,437 more jobs, according to the Massachusetts Life Sciences Center. However, the state's annual funding earmarked for the initiative has been reduced by budget cuts and tough economic conditions, said Susan Windham-Bannister, the center's chief executive. Boston Herald (10/1) - Health insurer to cover Genomic Health's colon cancer gene test
Genomic Health said Palmetto GBA, a health insurer and the national contractor for Medicare, has decided to cover its genetic test, Oncotype DX, for use in predicting the recurrence of colon cancer among patients with stage II colon cancer. The company said its test, which is also designed to predict the recurrence of breast cancer, can help cut health care costs by guiding physicians and patients when making treatment decisions. Xconomy/San Francisco (9/30) - G-Zero Therapeutics gets $3M NIH grant for "radiomitigants"
The National Institute of Allergy and Infectious Diseases awarded $3 million to G-Zero Therapeutics to develop "radiomitigants," or drugs that reduce toxic effects of chemotherapy and radiation exposure. The North Carolina firm develops the drugs using a small-molecule technology, which also has the ability to protect kidneys. MedCityNews.com (9/30)  | LET’S GO DESIGN: Episode #5
In this episode of SolidWorks’ interactive web series, Jeremy moves closer to the final design of our Hot Rod Baby Buggy and also hot-wires the golf cart motor to show how the aluminum tracks perform flawlessly. Watch at LetsGoDesign.tv. |
 | | | Most Popular Headlines from Last Week Results based on number of times each story was clicked by readers. |
| Hot Topics |  |  | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Feds to invest $156M in 60 "game-changing" energy projects
The Department of Energy said it will invest $156 million in 60 potentially "game-changing" initiatives that seek to develop, among other things, affordable next-generations biofuels. The funds will be made available through the Advanced Research Projects Agency-Energy. "These innovative projects are at the forefront of a new technological frontier that plays a critical role in our future energy security and economic growth," said ARPA-E Director Arun Majumdar. The Hill/E2 Wire blog (9/29) | News from BIO | | | | - BIO argues for a 21st century FDA
In this issue of FDLI's Food and Drug Law Policy Forum (Volume 1, Issue 18), James C. Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), answers this provocative question: Can a 21st Century FDA Accelerate Biotech Innovation to Cure Disease and Save Lives? Greenwood argues that Congress needs to elevate the agency to independent status (like EPA); that FDA must advance regulatory science and innovation through a chief innovation officer; and that FDA should enable modernized patient-centric clinical development, all to make FDA a truly effective regulatory agency. Read the article here.
| SmartQuote | | | |  | The man who trims himself to suit everybody will soon whittle himself away."
--Charles Schwab,
American businessman  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, September 30, 2011
- Thursday, September 29, 2011
- Wednesday, September 28, 2011
- Tuesday, September 27, 2011
- Monday, September 26, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment